- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
EGA Calls for Removal of Barriers to Generics in Europe
Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
Speaking at the 5th Bruges European Business Conference, van den Hoven maintained that the move would be in the interest of creating a pro-competitive pharmaceutical market in the EU and fostering sustainable competition.
He underlined the crucial role for Europe as a strong EU pharmaceutical export base, to be achieved through regulatory convergence with key trade partners and regulatory approximation in the EU with developing and emerging countries.
The Bruges conference was hosted by the College of Europe and included representatives from the European institutions, national governments and academia, and business leaders from all industrial sectors. Speakers included Dr. Wolfgang Schauble, German Minister of Finance and Prof. Mario Monti, former European Commissioner and Italian Prime Minister.
This entry was posted in
Europe
,
Events
,
Global
,
Regulatory
and tagged
Bruges European Business Conference
,
EGA
,
EU
,
European Generics Association
,
generics
. Bookmark the
permalink
. Trackbacks are closed, but you can
post a comment
.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
